AGS-499 / Neuromagen Pharma - LARVOL DELTA

Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis) (BioSpace) - “Neuromagen Pharma Ltd…has received FDA Orphan Drug Designation for AGS-499 its lead drug candidate, which has shown significant effectiveness in delaying the onset and progression of ALS (Amyotrophic Lateral Sclerosis)….This designation will provide Neuromagen with seven years of marketing exclusivity for AGS-499 following the approval and launch for ALS treatment....'We believe this treatment approach holds great potential and look forward to beginning clinical trials for AGS-499 while continuing to develop our pipeline.'”

Orphan drug • Amyotrophic Lateral Sclerosis • CNS Disorders